Expert opinion on emerging drugs for lung chronic graft-versus-host disease

Expert Opin Emerg Drugs. 2022 Jun;27(2):99-101. doi: 10.1080/14728214.2022.2089651. Epub 2022 Jun 22.

Authors

Giulia Gabrielli^{1

2}, Irene Dogliotti¹, Mauro Mangiapia³, Chiara Chiappero³, Jessica Gill^{1

2}, Chiara Maria Dellacasa¹, Alessandro Busca¹, Luisa Giaccone^{1

2}

Affiliations

¹ Stem Cell Transplant Unit, Azienda Ospedaliero Universitaria Città della Salute e della Scienza di Torino, Torino, Italy.
² Department of Molecular Biotechnology and Health Sciences, University of Torino, Torino, Italy.
³ Pneumology Unit, Department of cardiovascular and thoracic diseases, Azienda Ospedaliero Universitaria Città della Salute e della Scienza di Torino, Torino, Italy.

PMID: 35733295
DOI: 10.1080/14728214.2022.2089651

No abstract available

Keywords: BOS; HSCT; PFT; cGVHD; immunosuppressive therapy.

Publication types

Editorial

MeSH terms

Chronic Disease
Graft vs Host Disease* / drug therapy
Hematopoietic Stem Cell Transplantation*
Humans
Lung